✦ LIBER ✦

Clinical experience with infliximab therapy in the initial 256 infusions in patients with Crohn’s Disease at the Crohn’s and Colitis Center of New Jersey

✍ Scribed by Kenneth D Glazier; Manoj A Shirodkar; Emily Kosa; Zafar K Mirza; Louis H Griffel; Kiron M Das∗

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Infliximab therapy for Crohn's disease:

✍ Botros, Nashed; Griffel, Louis H.; Kosa, Emily M.; Prasad, Saket; Das, Kiron M. 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 196 KB

Immunomodulators and “on demand” therapy

✍ Timothy Kinney; Matthew Rawlins; Richard Kozarek; Renée France; David Patterson 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 170 KB

Clinical experience with infliximab and

✍ Riis, Åse; Martinsen, Tom C.; Waldum, Helge L.; Fossmark, Reidar 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 166 KB

The 10-year experience with purinethol (

✍ Glazier, Kenneth D.; Palance, Adam; Griffel, Louis H.; Das, Kiron M. 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 189 KB

The safety profile of infliximab in pati

✍ Jean-Frederic Colombel; Edward V. Loftus Jr; William J. Tremaine; Laurence J. Eg 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 145 KB

The impact of infliximab infusion reacti

✍ A. C. MOSS; N. FERNANDEZ-BECKER; K. JO KIM; D. CURY; A. S. CHEIFETZ 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB